Clinical Trial Update: Neural Biomarkers in Fragile X Syndrome

View source ↗

Summary

A completed clinical trial by Connecta Therapeutics investigating neural biomarkers in Fragile X syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Snippet

Sponsor: Connecta Therapeutics, S.L. | Conditions: Fragile X Syndrome (FXS), Neurotypical Adults | Status: COMPLETED